Elicit: Mechanism of Bictegravir in HIV-1 Integrase Inhibition

Mechanism of Bictegravir in HIV-1 Integrase Inhibition

How does bictegravir inhibit HIV-1 integrase strand transfer?

Bictegravir inhibits HIV-1 integrase strand transfer by binding at the integrase-DNA interface, coordinating catalytic Mg²⁺ ions through metal-chelating residues, and making π-stacking interactions with viral DNA that displace the 3' nucleotide and block the transfer reaction.

Abstract

Bictegravir inhibits HIV-1 integrase strand transfer by binding at the interface between two integrase protomers and viral DNA, where it coordinates with two catalytic Mg²⁺ ions through metal-chelating residues Asp64, Asp116, and Glu152. The drug specifically targets strand transfer activity with an IC50 of 7.5 nM while showing much weaker inhibition of 3’ processing (IC50 of 241 nM). Bictegravir’s trifluorobenzyl tail makes π-stacking interactions with the 39-deoxycytosine base of viral DNA, while its core ring stacks with the terminal 39-dA base. The drug’s unique bicyclic ring system makes additional van der Waals contacts with the β4-α2 loop and viral DNA, contributing to an exceptionally long dissociation half-life of 163 hours from integrase-DNA complexes—substantially longer than dolutegravir (96 hours), raltegravir (10 hours), or elvitegravir (3.3 hours). This extended residence time translates to more durable antiviral activity after drug washout.

Bictegravir’s superior resistance profile derives from structural flexibility and optimized binding interactions. The oxazepine ring’s flexibility allows the drug to adapt to active site geometry changes caused by resistance mutations, while its expanded chemical scaffold mediates critical backbone interactions that antagonize resistant viruses. Against 47 patient-derived isolates with high-level INSTI resistance, 13 showed >2-fold lower resistance to bictegravir than dolutegravir. However, specific mutation combinations can overcome bictegravir’s advantages: the G118R plus R263K double mutant confers 33.7-fold resistance, and Q148H/G140S mutations disrupt Mg²⁺ coordination, causing 5-8 fold resistance. All INSTIs share a fundamental dependence on optimal Mg²⁺ coordination that resistance mutations exploit.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

n = 200 Papers screened using: Bictegravir Mechanism Focus, Mechanistic Study Design, Binding Interactions or Resistance Data, HIV-1 Integrase System, Mechanistic Data Inclusion, Integrase Focus, Experimental Design

n = 200 Papers screened out

n = 190 Papers included for extraction

n = 10

Data extraction

Bictegravir Mechanism: Extract all mechanistic details about how bictegravir specifically inhibits HIV-1 integrase strand transfer, including:
- Molecular binding mechanism and target site
- Effects on strand transfer enzymatic process
- Inhibition kinetics (IC50, Ki values)
- Conformational changes induced in integrase/intasome
- Step-specific effects (3’ processing vs strand transfer)
- Any proposed mechanism of action models or pathways
Structural Interactions: Extract structural details of bictegravir-integrase interactions, including:
- Binding site location and residues involved
- Key molecular interactions (hydrogen bonds, hydrophobic contacts, metal coordination)
Resistance Mechanisms: Extract how specific resistance mutations affect bictegravir mechanism and activity, including:
- Which mutations confer bictegravir resistance and fold-change values
- Structural/mechanistic basis for how each mutation reduces bictegravir efficacy
Comparative Analysis: Extract comparisons between bictegravir and other integrase inhibitors regarding mechanism of action, including:
- Unique mechanistic features of bictegravir vs other INSTIs (raltegravir, elvitegravir, dolutegravir, etc.)
Experimental Methods: Extract experimental approaches used to study bictegravir mechanism, including:
- Assay types (biochemical, cell-based, structural)
- Key experimental conditions and controls
Study Scope: Extract what specific aspect of bictegravir mechanism was investigated, including:
- Primary research objective related to bictegravir mechanism

Molecular mechanism of bictegravir inhibition

Binding site and molecular interactions

Bictegravir binds within a well-defined pocket at the interface between two integrase protomers and viral DNA. The binding mechanism involves multiple critical molecular interactions. Bictegravir coordinates with two catalytic Mg²⁺ ions in the active site through its metal-binding pharmacophore, interacting with metal-chelating residues Asp64, Asp116, and Glu152.

Structurally, bictegravir makes intimate contacts with the backbone atoms of Asn117 and Gly118 and multiple contacts with the IN β4-α2 connector.

Inhibition of strand transfer activity

Bictegravir specifically targets HIV-1 integrase strand transfer activity with an IC50 of 7.5 ± 0.3 nM.

Dissociation kinetics and durability of inhibition

A critical mechanistic feature of bictegravir is its exceptionally long dissociation half-life from integrase-DNA complexes. Bictegravir has a dissociation t1/2 of 163 hours from wild-type integrase-DNA complexes, compared to dolutegravir (96 hours), raltegravir (10 hours), and elvitegravir (3.3 hours).

Structural basis for activity and resistance profile

Unique structural features

Bictegravir possesses unique structural features that distinguish it from other INSTIs. The drug contains a bridged bicyclic ring and a trisubstituted benzyl tail, allowing bictegravir to adapt to changes in active site geometry caused by resistance mutations.

Resistance mechanisms and mutations

Multiple resistance mutations affect bictegravir susceptibility through distinct mechanisms.

Comparative analysis with other integrase inhibitors

Bictegravir demonstrates superior activity against resistant variants compared to first-generation and some second-generation INSTIs. Against nine INSTI-resistant site-directed HIV-1 mutants, bictegravir displayed an improved resistance profile compared to raltegravir and elvitegravir, and comparable performance to dolutegravir.

Synthesis

The mechanistic data reveal that bictegravir’s superior resistance profile derives from multiple structural and kinetic advantages working synergistically.